Evidence map›Paper›PMID 37318610›Full record

ReviewMedical oncology (Northwood, London, England)2023

NK cells direct the perspective approaches to cancer immunotherapy.

Abduladheem Turki Jalil, Mohanad Ali Abdulhadi, Farah A Al-Marzook, Manar Mohammed Hizam, Sada Jasim Abdulameer, Abdul Kareem J Al-Azzawi, Rahman S Zabibah, Ali A Fadhil

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abduladheem Turki JalilDepartment of Medical Laboratories Techniques, Al-Mustaqbal University College, Hilla, Babylon, Iraq. abedalazeem799@gmail.com.ORCID http://orcid.org/0000-0001-8403-7465
Mohanad Ali AbdulhadiDepartment of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq.
Farah A Al-MarzookCollege of Medical and Health Technologies, Al-Zahraa University for Women, Karbala, 56100, Iraq.
Manar Mohammed HizamNational University of Science and Technology, Nasiriyah, Dhi Qar, Iraq.
Sada Jasim AbdulameerBiology Department, College of Education for Pure Science, Wasit University, Kut, Wasit, Iraq.
Abdul Kareem J Al-AzzawiDentistry Department, Al-Turath University College, Baghdad, Iraq.
Rahman S ZabibahMedical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.
Ali A FadhilMedical Technical College, Al-Farahidi University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are innate immune cells with cytotoxic potentials to kill cancerous cells in several mechanisms, which could be implied for cancer therapy. While potent, their antitumor activities specially for solid tumors impaired by inadequate tumor infiltration, suppressive tumor microenvironment, cancer-associated stroma cells, and tumor-supportive immune cells. Therefore, manipulating or reprogramming these barriers by prospective strategies might improve current immunotherapies in the clinic or introduce novel NK-based immunotherapies. NK-based immunotherapy could be developed in monotherapy or in combination with other therapeutic regimens such as oncolytic virus therapy and immune checkpoint blockade, as presented in this review.

Indexed as

Antineoplastic AgentsNeoplasmsHumansImmunotherapyImmunotherapy, AdoptiveKiller Cells, NaturalProspective StudiesTumor MicroenvironmentAntineoplastic AgentsCancer immunotherapyChimeric antigen receptorOncolytic virusesTargeted therapyTumor microenvironment

Identifiers

PMID37318610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.